GILD—Musings on POLARIS studies of 3-DAA HCV regimen:
All told, the results reported today for SOF/VEL/VOX are nothing special, IMO. POLARIS-2—the main SOF/VEL/VOX trial in treatment-naïve patients—actually failed its primary endpoint of showing non-inferiority to Epclusa (SOF/VEL 2-DAA):
The SOF/VEL/VOX arm in POLARIS-2 not only failed fail to achieve statsig non-inferiority to the Epclusa arm, but also was numerically worse than the Epclusa arm on SVR12 (95% vs 98%).
Although an 8-week regimen of SOF/VEL/VOX worked as well as Epclusa in the (smaller) POLARIS-3 trial for treatment-naïve cirrhotic patients, the POLARIS-2 results call into question whether 8 weeks is an appropriate duration for SOF/VEL/VOX in treatment-naïve patients.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.